Investigating the expression pattern of the angiopoietin-Tie system in ALL and its correlation with baseline characteristics

Abstract

Background: Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children.Several environmental and genetic factors are known to be involved in its development and progression. The angiopoietin-Tie system is one of the most critical factors in angiogenesis, and its possible role in solid tumors and leukemia has been previously investigated. In this study, we examined the expression of these genes in ALL patients (early pre-B-ALL and pre-B-ALL) and compared them with normal samples.Methods: Bone marrow samples were collected from 40 patients (aged 0-19 yr) newly diagnosed with early pre-B-ALL or pre-B-ALL using molecular and flow cytometric tests and from 15 control individuals. For molecular tests, RNA extraction and cDNA synthesis were performed, and Ang1, Ang2, Ang4, Tie1, and Tie2 gene expression was examined by real-time polymerase chain reaction.Results: Ang2, Tie1, and Tie2 gene expression were significantly increased in patients with ALL, whereas Ang1 gene expression was decreased. The Ang4 gene did not show significant expression changes between the two groups. Conclusion:Changes in the expression of the Ang-Tie system indicate a possible role of angiogenesis in ALL prognosis. Moreover, such changes can be considered as potential diagnostic biomarkers or therapeutic targets.

Applications of single‐cell omics for chimeric antigen receptor T cell therapy

“…The transfer of CAR-coding gene into host T cell genome is done using γ-retroviral or lentiviral vectors, electroporation or using CRISPR/Cas9 or other gene-editing platforms for a precise integration [3]. The CAR T cells are then expanded and infused into the patient where, upon antigen binding, activate and differentiate into effector T cells, some of which go on to become memory T cells for long-term immunity [4][5][6]. Despite the high cost of CAR T therapy, efforts are being made to turn them into a mainstream modality of cancer treatment.…”